The European medicines agency review of pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: Summary of the scientific assessment of the committee for medicinal products for human use

Oncologist

Volumn 19, Issue 7, 2014, Pages 766-773

  Boix Perales, Hector ^a   Borregaard, Jeanett ^b   Jensen, Kristina Bech ^b   Ersbøll, Jens ^b   Galluzzo, Sara ^c   Giuliani, Rosa ^d   Ciceroni, Cinzia ^d   Melchiorri, Daniela ^d   Salmonson, Tomas ^e   Bergh, Jonas ^f   Schellens, Jan H ^g   Pignatti, Francesco ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b Danish Health and Medicines Authority   (Denmark)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d ITALIAN MEDICINES AGENCY   (Italy)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; EMA; European medicines agency; Perjeta; Pertuzumab

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; PERTUZUMAB; PLACEBO; RO 4368451; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BREAST CANCER; BREAST METASTASIS; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSGEUSIA; DYSPEPSIA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LACRIMATION DISORDER; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOPENIA; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; RISK ASSESSMENT; STOMATITIS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BREAST NEOPLASMS; EUROPEAN UNION; FEMALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EUROPEAN UNION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 84903641743     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0348     Document Type: Article

References (19)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2013. Ann Oncol 2013;24:792-800.
3. Adams CW, Allison DE, Flagella K et al. Humanizationofarecombinantmonoclonalantibodytoproduce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55:717-727.
4. Franklin MC, Carey KD, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-328.
5. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-2346.
6. Scheuer W, Friess T, Burtscher H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-9336.
7. Malik S, Totpal K, Balter I et al. Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models [abstract 773]. Proc Am Assoc Cancer Res 2003;44:150.
8. Attard G, Kitzen J, Blagden SP et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 2007;97: 1338-1343.
9. Makhija S, Amler LC, Glenn D et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010;28:1215-1223.
10. Felip E, Ranson M, Cedres S et al. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2012;13:432-441.
11. Albanell J, Montagut C, Jones ET et al. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res 2008;14:2726-2731.
12. Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-2543.
13. Ng CM, Lum BL, Gimenez V et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006;23:1275-1284.
14. Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24: 4324-4332.
15. de Bono JS, Bellmunt J, Attard G et al. Openlabel phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormonerefractory prostate cancer. J Clin Oncol 2007;25: 257-262.
16. Baselga J, Cortes J, KimSB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366: 109-119.
17. Baselga J, Cortés J, Im SA et al. Biomarker analyses in CLEOPATRA: A phase III, placebocontrolled study of pertuzumab in HER2-positive, first-linemetastaticbreastcancer (MBC). Cancer Res 2012;72(suppl 3):S5-1.
18. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010;21(suppl 5): v248-v251.
19. Swain SM, Kim SB, Cortés J et al. Pertuzumab, trastuzumab, anddocetaxel forHER2-positivemetastatic breastcancer(CLEOPATRAstudy):Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-471.